Spectrum Pharmaceuticals Toekomstige groei

Future criteriumcontroles 5/6

De verwachting is dat Spectrum Pharmaceuticals de winst en omzet met respectievelijk 67.3% en 35.5% per jaar zal laten groeien, terwijl de winst per aandeel naar verwachting zal groeien met 75.4% per jaar.

Belangrijke informatie

67.3%

Groei van de winst

75.4%

Groei van de winst per aandeel

Biotechs winstgroei	28.4%
Inkomstengroei	35.5%
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	Low
Laatst bijgewerkt	25 Jul 2023

Recente toekomstige groei-updates

Earnings Update: Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) Just Reported And Analysts Are Boosting Their Estimates

May 12

Recent updates

Analysts Just Made A Huge Upgrade To Their Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) Forecasts

May 14

Earnings Update: Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) Just Reported And Analysts Are Boosting Their Estimates

May 12

Spectrum plunges 28% after FDA scientists question poziotinib evidence for NSCLC

Sep 20

Is Spectrum Pharmaceuticals (NASDAQ:SPPI) In A Good Position To Invest In Growth?

Sep 16

Spectrum Pharmaceuticals stock jumps 10% afterhours on FDA nod for Rolvedon injection

Sep 09

Spectrum Pharmaceuticals: Revisiting This 'Soap Opera'

Aug 21

Spectrum Pharmaceuticals Q2 2022 Earnings Preview

Aug 10

Here's Why We're A Bit Worried About Spectrum Pharmaceuticals' (NASDAQ:SPPI) Cash Burn Situation

Jun 04

Spectrum Pharmaceuticals: Some Last Words

Feb 25

Here's Why We're Watching Spectrum Pharmaceuticals' (NASDAQ:SPPI) Cash Burn Situation

Oct 05

Here's Why We're Watching Spectrum Pharmaceuticals' (NASDAQ:SPPI) Cash Burn Situation

May 31

We're Keeping An Eye On Spectrum Pharmaceuticals' (NASDAQ:SPPI) Cash Burn Rate

Feb 12

Spectrum Pharma drops after announcing less-than-favorable Phase 2 data

Dec 22

Here's What Spectrum Pharmaceuticals, Inc.'s (NASDAQ:SPPI) Shareholder Ownership Structure Looks Like

Dec 21

Spectrum Pharma Is Down But Not Out

Nov 16

Spectrum Shareholders In Limbo As FDA Delays Rolontis Decision Date, Agrees To Discuss Poziotinib

Nov 11

Winst- en omzetgroeiprognoses

NasdaqCM:SPPI - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2025	201	97	36	141	4
12/31/2024	127	14	18	36	5
12/31/2023	73	-18	-21	2	3
3/31/2023	26	-68	-88	-88	N/A
12/31/2022	10	-78	-97	-97	N/A
9/30/2022	N/A	-106	-102	-102	N/A
6/30/2022	N/A	-117	-109	-109	N/A
3/31/2022	N/A	-138	-115	-115	N/A
12/31/2021	N/A	-158	-120	-119	N/A
9/30/2021	N/A	-169	-121	-122	N/A
6/30/2021	N/A	-184	-127	-125	N/A
3/31/2021	N/A	-166	-127	-123	N/A
12/31/2020	N/A	-171	-127	-122	N/A
9/30/2020	N/A	-162	-127	-120	N/A
6/30/2020	N/A	-140	-131	-119	N/A
3/31/2020	N/A	-136	-138	-128	N/A
12/31/2019	N/A	-135	-144	-135	N/A
9/30/2019	N/A	-148	-127	-116	N/A
6/30/2019	N/A	-191	-103	-100	N/A
3/31/2019	N/A	-147	-79	-76	N/A
12/31/2018	N/A	-127	-65	-62	N/A
9/30/2018	29	-102	-63	-63	N/A
6/30/2018	65	-51	-59	-59	N/A
3/31/2018	99	-87	-46	-45	N/A
12/31/2017	N/A	-101	-39	-39	N/A
9/30/2017	135	-81	-30	-29	N/A
6/30/2017	132	-81	-36	-36	N/A
3/31/2017	132	-84	-54	-54	N/A
12/31/2016	146	-70	N/A	-40	N/A
9/30/2016	162	-55	N/A	-34	N/A
6/30/2016	157	-56	N/A	-30	N/A
3/31/2016	168	-35	N/A	5	N/A
12/31/2015	163	-53	N/A	7	N/A
9/30/2015	164	-50	N/A	15	N/A
6/30/2015	183	-42	N/A	34	N/A
3/31/2015	185	-44	N/A	31	N/A
12/31/2014	187	-46	N/A	-4	N/A
9/30/2014	176	-82	N/A	-7	N/A
6/30/2014	171	-78	N/A	-30	N/A
3/31/2014	157	-84	N/A	-64	N/A
12/31/2013	156	-62	N/A	-2	N/A
9/30/2013	184	-15	N/A	-2	N/A
6/30/2013	211	14	N/A	30	N/A
3/31/2013	247	42	N/A	67	N/A
12/31/2012	268	94	N/A	72	N/A
9/30/2012	251	95	N/A	75	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: Er wordt voorspeld dat SPPI de komende 3 jaar winstgevend zal worden, wat wordt beschouwd als een snellere groei dan de spaarquote ( 2.1% ).

Winst versus markt: Er wordt verwacht dat SPPI de komende 3 jaar winstgevend zal worden. Dit wordt gezien als een groei die boven het gemiddelde van de markt ligt.

Hoge groeiwinsten: Er wordt verwacht dat SPPI binnen 3 jaar winstgevend zal worden.

Omzet versus markt: De omzet van SPPI ( 35.5% per jaar) zal naar verwachting sneller groeien dan de markt US ( 9% per jaar).

Hoge groei-inkomsten: De omzet van SPPI ( 35.5% per jaar) zal naar verwachting sneller groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van SPPI naar verwachting over 3 jaar hoog zal zijn

Spectrum Pharmaceuticals Toekomstige groei

Future criteriumcontroles 5/6

Belangrijke informatie

Recente toekomstige groei-updates

Consensus estimates of losses per share improve by 38%

Consensus revenue estimates increase by 23%

Price target decreased by 33% to US$1.26

Earnings Update: Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) Just Reported And Analysts Are Boosting Their Estimates

Forecast breakeven date moved forward to 2024

Consensus EPS estimates upgraded to US$0.17 loss

Recent updates

Spectrum Pharmaceuticals, Inc. Files Form 15

Spectrum Pharmaceuticals, Inc.(NasdaqCM:SPPI) dropped from NASDAQ Composite Index

Assertio Holdings, Inc. (NasdaqCM : ASRT) completed the acquisition of Spectrum Pharmaceuticals, Inc. (NasdaqGS : SPPI).

Consensus estimates of losses per share improve by 38%

Spectrum Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement

Consensus revenue estimates increase by 23%

Analysts Just Made A Huge Upgrade To Their Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) Forecasts

Price target decreased by 33% to US$1.26

Earnings Update: Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) Just Reported And Analysts Are Boosting Their Estimates

Forecast breakeven date moved forward to 2024

Consensus EPS estimates upgraded to US$0.17 loss

Price target decreased by 15% to US$2.65

Spectrum Pharmaceuticals, Inc. Receives Permanent J-Code for ROLVEDON Injection (J1449) from U.S. Centers for Medicare & Medicaid Services

President notifies of intention to sell stock

Consensus revenue estimates increase by 161%

Spectrum Pharmaceuticals, Inc. Provides Sales Guidance for the Quarter Ended December 31, 2022

Spectrum Pharmaceuticals Announces Executive Changes

Forecast to breakeven in 2025

Robbins LLP Reminds Investors of Lead Plaintiff Deadline in Class Action Against Spectrum Pharmaceuticals, Inc

Spectrum Pharmaceuticals’ ROLVEDON™ Injection Added to NCCN Supportive Care Guidelines in Oncology for Hematopoietic Growth Factors

Consensus revenue estimates increase by 16%

Spectrum Pharmaceuticals, Inc. Receives Complete Response Letter from U.S. Food and Drug Administration for Poziotinib; Reaffirms Focus on the Commercialization of ROLVEDON™ (eflapegrastim-xnst) injection

Price target decreased to US$3.10

Price target decreased to US$4.13

Spectrum Pharmaceuticals Receives Written Notice from Nasdaq Regarding Minimum Bid Price Requirement

Spectrum Pharmaceuticals Announces Commercial Availability of Rolvedon™ (Eflapegrastim-Xnst) Injection

No longer forecast to breakeven

Spectrum Pharmaceuticals, Inc. Provides Update on Poziotinib Following FDA Oncologic Drugs Advisory Committee Meeting

Price target decreased to US$5.40

Spectrum plunges 28% after FDA scientists question poziotinib evidence for NSCLC

Is Spectrum Pharmaceuticals (NASDAQ:SPPI) In A Good Position To Invest In Growth?

Consensus forecasts updated

Spectrum Pharmaceuticals Receives Food and Drug Administration Approval for ROLVEDON (eflapegrastim-xnst) Injection

Spectrum Pharmaceuticals stock jumps 10% afterhours on FDA nod for Rolvedon injection

Spectrum Pharmaceuticals: Revisiting This 'Soap Opera'

Consensus revenue estimates fall by 61%

Spectrum Pharmaceuticals Q2 2022 Earnings Preview

Spectrum Pharmaceuticals Receives Non-Compliance Letter from Nasdaq

Here's Why We're A Bit Worried About Spectrum Pharmaceuticals' (NASDAQ:SPPI) Cash Burn Situation

Consensus forecasts updated

Spectrum Pharmaceuticals, Inc. Appoints Nora E. Brennan as Chief Financial Officer

Spectrum Pharmaceuticals Appoints Brittany K. Bradrick to its Board of Directors

Price target decreased to US$5.60

Spectrum Pharmaceuticals Announces FDA Acceptance of BLA Resubmission for Eflapegrastim

Price target decreased to US$5.60

Spectrum Pharmaceuticals: Some Last Words

Spectrum Pharmaceuticals, Inc. Announces Resignation of Kurt Gustafson as Chief Financial Officer

Spectrum Pharmaceuticals, Inc. Announces Acceptance of New Drug Application Filing for Poziotinib

Spectrum Pharmaceuticals Announces Strategic Restructuring

Forecast to breakeven in 2024

Here's Why We're Watching Spectrum Pharmaceuticals' (NASDAQ:SPPI) Cash Burn Situation

Spectrum Pharmaceuticals, Inc. Presents Late Breaker Oral Presentation of Poziotinib Data in First-Line NSCLC Patients with HER2 Exon 20 Insertion Mutations at European Society for Medical Oncology Congress 2021

Pomerantz LLP Announces the Filing of Class Action Against Spectrum Pharmaceuticals, Inc and Certain Officers

Consensus revenue estimates fall to US$2.30m

Spectrum Pharmaceuticals' CRL: There Is Very Little Clarity

Spectrum Pharmaceuticals Receives Complete Response Letter from FDA for ROLONTIS® (eflapegrastim)

No longer forecast to breakeven

Price target decreased to US$9.40

High number of new directors

Spectrum's Big Approval: Any Day Now

Spectrum Pharmaceuticals, Inc.(NasdaqGS:SPPI) dropped from Russell 3000E Value Index

Consensus revenue estimates fall to US$20.0m

Spectrum Pharmaceuticals Presents Poziotinib Data in Patients with Brain Metastases from the Zenith20 Clinical Trial

Spectrum Pharmaceuticals Announces Initiation of Pre-Approval Inspection for ROLONTIS®

FDA initiates pre-approval inspection for Spectrum pharmaceuticals' ROLONTIS

Here's Why We're Watching Spectrum Pharmaceuticals' (NASDAQ:SPPI) Cash Burn Situation

Forecast breakeven pushed back to 2024

Consensus forecasts updated

FDA Grants Fast Track Designation to Spectrum Pharmaceuticals, Inc.'s Poziotinib